Danaher Upgrades Localization Strategy with 'Dual Innovation Acceleration Engine' to Empower Healthcare Ecosystem

ShanghaiNovember 10, 2023/PR Newswire/ -- On November 7, 2023, at the sixth CIIE, Danaher announced the upgrade of its "Create and Elevate China" local strategy, releasing"Dual Innovation Acceleration Engine" Framework, accelerate clinical innovation transformation, and empower industrial development.

Danaher's "Dual Innovation Acceleration Engine" focuses on innovation origination in medical institutions and enterprise empowerment in industrial parks, deeply connecting governments, hospitals, universities, research institutions, enterprises, and capital to integrate policy chains, industry chains, talent chains, innovation chains, funding chains, and ecosystem chains.

Peng, Global Vice President of Danaher and President of Danaher ChinaYang pointed out that Danaher "Innovation ElevateThe "China 2.0" strategy is dedicated to stimulating the innovative transformation vitality of medical institutions, promoting the spillover effects of clinical innovation; assisting in the deep integration of the entire industry chain, accumulating synergistic development momentum, thereby serving the rapid development of China's healthcare事业.

Clinical Innovation and Transformation of Innovative Source

Danaher Establishes Clinical Innovation and Transformation Accelerator, Collaborating with the Precision Medicine Research and Industry Development Alliance and the Beijing Medical and Health Science and Technology Promotion Center. Teaming up with renowned enterprises and professional institutions that possess both industrial and investment attributes, a close-knit industry alliance has been formed to accelerate clinical innovation and transformation in disease areas such as cancer, brain health, and autoimmune diseases, serving the health needs of more patients.

Huang Gang, Vice Chairman of the Precision Medicine Research and Industry Development Alliance, emphasized that Danaher's "Create and Elevate China" strategy will play a positive and irreplaceable role in the future development of the life sciences sector. The Alliance looks forward to collaborating with Danaher to promote innovative implementation from theory to practice, from models to technology, bringing more significant impacts on the health of the Chinese people and the global population.

Zhang Jingbo, Director of Beijing Medical and Health Science and Technology Promotion Center (Beijing Medical Institution Drug Use Monitoring and Evaluation Center), stated that in the field of clinical transformation, medical institutions are one of the key players, acting as both developers and validators, as well as users and promoters. Clinical innovation and transformation will play a crucial role in improving the quality and safety of patient care, benefiting more patients. As one of the first initiating units of the Capital Medical Science and Technology Innovation and Transformation Alliance, Danaher Corporation will collaborate with the center to jointly advance the transformation of scientific and technological achievements.

Empowering Industrial Development: 1+3+X Park Cooperation

Danaher Establishes Industrial Innovation Accelerator, Partnering with Government, Industry, Academia, Research, Medicine, and Investment in Key Strategic Regions like the Yangtze River Delta, Beijing-Tianjin-Hebei, Guangdong-Hong Kong-Macao, Chengdu-Chongqing, and More to Build a Closed-Loop of "Innovation Chain + Industrial Chain + Ecosystem." During the CIIE, Danaher Announced Collaborations with MOFCOM Investment Promotion Agency, Zean Biotech, and Firestone Creation to Drive Industrial Innovation.Transformation.

DanaherDanaher Announces Collaboration with Zhi'en Biotech to Build Danaher Western China Center, Supporting Innovation and Development in the Region's Biomedical Industry through a Strong Partnership. Leveraging the Leading Roles of Both Enterprises, They Will Focus on Joint Construction. The Two Parties Will Commit to Integrating the "Danaher Western China Center" into the Chengdu-Chongqing Economic Belt and Western Region’s Pharmaceutical R&D, Establishing a Scientific, Open, and Shared Platform for R&D, Manufacturing, and Testing. This Initiative Aims to Attract Numerous Supply Chain Companies, Construct a High-Quality Closed-Loop Industrial Chain, Promote the Integration of the Industrial Chain, Innovation Chain, and Service Chain ("Three-Chain Integration"), and Develop an Industrial Cluster Marked by Medical Diagnostics, Biologics, and Precision Therapies.

Huangshan, Chairman of Zhi'en Biotechnology Co., Ltd., pointed out that our goal is to achieve a win-win situation for both parties while fully leveraging the influence of the "Danaher Western China Center" to continuously support the high-quality development of China's pharmaceutical and healthcare industry.

Jin Xia, Chairman of Huoshi Creation, pointed out that Huoshi Creation provides an industry brain for the development of park industries with a unique perspective and strong industrial ecosystem capabilities. Deeply cultivating the life and health industry, it drives industrial development with data and will collaborate with Danaher to serve the park, thereby serving the industry.